Table of Contents Author Guidelines Submit a Manuscript
Corrigendum

A corrigendum for this article has been published. To view the corrigendum, please click here.

Case Reports in Rheumatology
Volume 2014, Article ID 458231, 4 pages
http://dx.doi.org/10.1155/2014/458231
Case Report

High-Dose Subcutaneous Immunoglobulins for the Treatment of Severe Treatment-Resistant Polymyositis

1Department of Internal Medicine, Pitié-Salpetrière Hospital Group, 47-83 Boulevard de l’Hôpital, 75013 Paris, France
2Octapharma, 92100 Boulogne-Billancourt, France
3Clinique Mutualiste Catalane, 66000 Perpignan, France

Received 14 May 2014; Revised 9 July 2014; Accepted 10 July 2014; Published 16 July 2014

Academic Editor: Masataka Kuwana

Copyright © 2014 Cherin Patrick et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. Marie, E. Hachulla, P.-Y. Hatron et al., “Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis,” Journal of Rheumatology, vol. 28, no. 10, pp. 2230–2237, 2001. View at Google Scholar · View at Scopus
  2. I. Marie, P. Y. Hatron, S. Dominique, P. Cherin, L. Mouthon, and J. Menard, “Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients,” Arthritis and Rheumatism, vol. 63, no. 11, pp. 3439–3447, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. I. Marie, L. Lahaxe, O. Benveniste et al., “Long-term outcome of patients with polymyositis/ dermatomyositis and anti-PM-Scl antibody,” British Journal of Dermatology, vol. 162, no. 2, pp. 337–344, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. T. A. Medsger Jr., W. N. Dawson Jr., and A. T. Masi, “The epidemiology of polymyositis,” The American Journal of Medicine, vol. 48, no. 6, pp. 715–723, 1970. View at Publisher · View at Google Scholar · View at Scopus
  5. I. Marie and L. Mouthon, “Therapy of polymyositis and dermatomyositis,” Autoimmunity Reviews, vol. 11, no. 1, pp. 6–13, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. P. Cherin, S. Herson, B. Wechsler et al., “Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients,” The American Journal of Medicine, vol. 91, no. 2, pp. 162–168, 1991. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Cherin, S. Pelletier, A. Teixeira et al., “Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients,” Arthritis & Rheumatism, vol. 46, no. 2, pp. 467–474, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. I. Elovaara, S. Apostolski, P. Van Doorn et al., “EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases,” European Journal of Neurology, vol. 15, no. 9, pp. 893–908, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. J. E. Hoogendijk, A. A. Amato, B. R. Lecky et al., “119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands,” Neuromuscular Disorders, vol. 14, no. 5, pp. 337–345, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Gold, M. Stangel, and M. C. Dalakas, “Drug Insight: The use of intravenous immunoglobulin in neurology—therapeutic considerations and practical issues,” Nature Clinical Practice Neurology, vol. 3, no. 1, pp. 36–44, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. P. Dacci, N. Riva, M. Scarlato et al., “Subcutaneous immunoglobulin therapy for the treatment of multifocal motor neuropathy: a case report,” Neurological Sciences, vol. 31, no. 6, pp. 829–831, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Harbo, H. Andersen, and J. Jakobsen, “Long-term therapy with high doses of subcutaneous immunoglobulin in multifocal motor neuropathy,” Neurology, vol. 75, no. 15, pp. 1377–1380, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. D.-H. Lee, R. A. Linker, W. Paulus, C. Schneider-Gold, A. Chan, and R. Gold, “Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy,” Muscle & Nerve, vol. 37, no. 3, pp. 406–409, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Pars, N. Garde, T. Skripuletz, R. Pul, R. Dengler, and M. Stangel, “Subcutaneous immunoglobulin treatment of inclusion-body myositis stabilizes dysphagia,” Muscle and Nerve, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. F. Eftimov, M. Vermeulen, R. J. de Haan, L. H. van den Berg, and I. N. van Schaik, “Subcutaneous immunoglobulin therapy for multifocal motor neuropathy,” Journal of the Peripheral Nervous System, vol. 14, no. 2, pp. 93–100, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. L. H. Markvardsen, J.-C. Debost, T. Harbo et al., “Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy,” European Journal of Neurology, vol. 20, no. 5, pp. 836–842, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. M. G. Danieli, L. Pettinari, R. Moretti, F. Logullo, and A. Gabrielli, “Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application,” Autoimmunity Reviews, vol. 10, no. 3, pp. 144–149, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. M. G. Danieli, R. Moretti, S. Gambini, L. Paolini, and A. Gabrielli, “Open-label study on treatment with 20% subcutaneous IgG administration in polymyositis and dermatomyositis,” Clinical Rheumatology, vol. 33, no. 4, pp. 531–536, 2014. View at Publisher · View at Google Scholar
  19. H. D. Ochs, S. Gupta, P. Kiessling, U. Nicolay, and M. Berger, “Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases,” Journal of Clinical Immunology, vol. 26, no. 3, pp. 265–273, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. I. Quinti, A. Soresina, C. Agostini et al., “Prospective study on CVID patients with adverse reactions to intravenous or subcutaneous IgG administration,” Journal of Clinical Immunology, vol. 28, no. 3, pp. 263–267, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Lazzaro, L. Lopiano, and D. Cocito, “Subcutaneous vs intravenous administration of immunoglobulin in chronic inflammatory demyelinating polyne uropathy: an Italian cost-minimization analysis,” Neurological Sciences, vol. 35, no. 7, pp. 1023–1034, 2014. View at Publisher · View at Google Scholar
  22. J. M. Kittner, B. Grimbacher, W. Wulff, B. Jäger, and R. E. Schmidt, “Patients' attitude to subcutaneous immunoglobulin substitution as home therapy,” Journal of Clinical Immunology, vol. 26, no. 4, pp. 400–405, 2006. View at Publisher · View at Google Scholar · View at Scopus